Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection

Journal of Virology

Volumn 74, Issue 16, 2000, Pages 7485-7495

  Egan, M A ^a   Charini, W A ^a   Kuroda, M J ^a   Schmitz, J E ^a   Racz, P ^a   Tenner Racz, K ^a   Manson, K ^a   Wyand, M ^a   Lifton, M A ^a   Nickerson, C E ^a   Fu, T ^a   Shiver, J W ^a   Letvin, N L ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MONKEY DISEASE; NONHUMAN; PLASMID; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VIRUS REPLICATION;

ANIMALS; CD4 LYMPHOCYTE COUNT; GENE PRODUCTS, GAG; HUMANS; LYMPH NODES; MACACA MULATTA; RNA, VIRAL; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VACCINES, DNA; VIRAL LOAD; VIRUS REPLICATION;

EID: 0033868431     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.16.7485-7495.2000     Document Type: Article

References (49)

1. Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus
2. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/1g administration
3. Mucosal immunization with HIV-1 pep-tide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge
4. HIV-1 DNA based vaccine induces a CD8 mediated cross-clade CTL response
5. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination
6. In vivo protective anti-HIV immune responses in non-human primates through DNA immunization
7. DNA vaccines
8. + cytotoxic T lymphocytes specific for dominant and nondominant viral epitopes in simian-human immunodeficiency virus-infected rhesus monkeys
9. A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine
10. Pattern of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: Effect of prior immunization With a trivalent SIV vaccine in modified vaccinia virus
11. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160
12. Effect of immunization with a vaccinia-HIV env recombinant on H1V infection of chimpanzees
13. Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection
14. A high frequency of Mamu-A*01 in the rhesus macaque detected by polymerase chain reaction with sequence-specific primers and direct sequencing
15. Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex
16. Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys
17. Comparative analysis of cytotoxic T lymphocytes in lymph nodes and peripheral blood of simian immunodeficiency virus-infected rhesus monkeys
18. Synthetic oligonucleotide probes deduced from amino acid sequence data. Theoretical and practical considerations
19. HIV-1 env DNA vaccine administered to rhesus monkeys elicits MHC class II-restricted CD4+ T helper cells that secrete IFN-gamma and TNF-alpha
20. Animal models for the study of human immunodeficiency virus infections
21. Progress in the development of an HIV-1 vaccine
22. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination
23. The extem of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection
24. DNA vaccines. Mechanisms for generation of immune responses
25. Vaccination of mice and nonhuman primates using HIV-gene-containing DNA
26. Simian immunodeficiency virus DNA vaccine trial in macaques
27. DNA vaccines
28. Vaccination of rhesus monkeys with synthetic peptide in a fusogenic proteoliposome elicits simian immunodeficiency virus-specific CD8+ cytotoxic T lymphocytes
29. Definition of an epitope and MHC class I molecule recognized by gag-specific cytotoxic T lymphocytes in SIVmac-infected rhesus monkeys
30. Heterologous and homologous protection against influenza A by DNA vaccination: Optimization of DNA vectors
31. DNA vaccines
32. DNA vaccines
33. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
34. Adjuvant is required when using Env lipopeptide construct to induce HIV type 1-specific neutralizing antibody responses in mice in vivo
35. Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer
36. Recombinant virus-vaccine-induced SIV-specific CDS+ cytotoxic T lymphocytes
37. Humoral and cellular immunities elicited by HIV-1 vaccination
38. Anti-HIV env immunities elicited by nucleic acid vaccines
39. Cytotoxic T lymphocyte and helper T cell responses following H1V polynu-cleotide vaccination
40. Mucosal immunity to HIV-1: Systemic and vaginal antibody respdfises after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A)
41. Plasma SIV RNA viral load determination by real-time quantification of product generation in reverse transcriptase-polymerase chain reaction
42. The unenlarged lymph nodes of HIV-1-infected, asymptomatic patients with high CD4 T cell counts are sites for virus replication and CD4 T cell proliferation. The impact of highly active antiretroviral therapy
43. DNA vaccines for bacteria and viruses
44. Toward the development of DNA vaccines
45. DNA inoculation induces neutralizing immune responses against human immunodeficiency virus type 1 in mice and nonhuman primates
46. Induction of humoral and cellular immune responses to the human immunodeficiency virus type 1 virus in nonhuman primates by in vivo DNA inoculation
47. Gene inoculation generates immune responses against human immunodeficiency virus type 1
48. Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys